 Joshua Barocas
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 27 | 2023 | 417 | 9.540 |
Why?
| | Drug Overdose | 19 | 2023 | 294 | 6.310 |
Why?
| | Substance Abuse, Intravenous | 11 | 2022 | 80 | 6.030 |
Why?
| | Hepatitis C | 10 | 2022 | 217 | 4.230 |
Why?
| | Endocarditis | 6 | 2023 | 33 | 3.530 |
Why?
| | Analgesics, Opioid | 19 | 2023 | 794 | 2.500 |
Why?
| | Pharmaceutical Preparations | 6 | 2021 | 167 | 2.490 |
Why?
| | Buprenorphine | 8 | 2023 | 136 | 2.300 |
Why?
| | Hepatitis C, Chronic | 4 | 2021 | 151 | 2.210 |
Why?
| | Epidemics | 3 | 2022 | 70 | 2.090 |
Why?
| | Endocarditis, Bacterial | 4 | 2023 | 37 | 2.050 |
Why?
| | Substance-Related Disorders | 9 | 2023 | 971 | 1.940 |
Why?
| | Hepacivirus | 8 | 2022 | 230 | 1.900 |
Why?
| | HIV Infections | 10 | 2022 | 2459 | 1.690 |
Why?
| | Soft Tissue Infections | 2 | 2021 | 30 | 1.510 |
Why?
| | Cost-Benefit Analysis | 10 | 2023 | 554 | 1.500 |
Why?
| | Drug Users | 3 | 2022 | 39 | 1.480 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 3 | 2022 | 10 | 1.430 |
Why?
| | Prisoners | 2 | 2022 | 128 | 1.410 |
Why?
| | Central Nervous System Stimulants | 2 | 2022 | 142 | 1.370 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 227 | 1.310 |
Why?
| | Naloxone | 2 | 2021 | 98 | 1.240 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 348 | 1.170 |
Why?
| | Coronavirus Infections | 3 | 2020 | 339 | 1.160 |
Why?
| | Humans | 78 | 2023 | 118974 | 1.140 |
Why?
| | Housing | 3 | 2023 | 123 | 1.130 |
Why?
| | Fentanyl | 2 | 2023 | 70 | 1.080 |
Why?
| | Massachusetts | 7 | 2023 | 141 | 1.040 |
Why?
| | Opiate Substitution Treatment | 5 | 2022 | 96 | 1.040 |
Why?
| | Patient Isolation | 2 | 2021 | 19 | 0.990 |
Why?
| | Referral and Consultation | 3 | 2022 | 648 | 0.980 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2020 | 42 | 0.930 |
Why?
| | Antiviral Agents | 5 | 2022 | 654 | 0.920 |
Why?
| | Narcotic Antagonists | 4 | 2022 | 136 | 0.910 |
Why?
| | Health Personnel | 2 | 2020 | 588 | 0.890 |
Why?
| | Mass Screening | 6 | 2020 | 1052 | 0.870 |
Why?
| | Preventive Health Services | 2 | 2020 | 135 | 0.840 |
Why?
| | Crisis Intervention | 1 | 2021 | 25 | 0.830 |
Why?
| | Hospital Administration | 1 | 2021 | 21 | 0.830 |
Why?
| | Prevalence | 10 | 2023 | 2326 | 0.810 |
Why?
| | Criminal Law | 1 | 2021 | 26 | 0.800 |
Why?
| | Liver Cirrhosis | 2 | 2022 | 245 | 0.790 |
Why?
| | Hospitalization | 7 | 2022 | 1785 | 0.790 |
Why?
| | Convalescence | 1 | 2021 | 15 | 0.790 |
Why?
| | Hospital Units | 1 | 2021 | 24 | 0.790 |
Why?
| | Communicable Diseases | 2 | 2021 | 132 | 0.780 |
Why?
| | Public Health | 3 | 2023 | 450 | 0.780 |
Why?
| | United States | 16 | 2023 | 12555 | 0.780 |
Why?
| | Adult | 27 | 2023 | 31512 | 0.770 |
Why?
| | Health Communication | 1 | 2021 | 44 | 0.760 |
Why?
| | Residential Treatment | 1 | 2020 | 31 | 0.760 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2022 | 174 | 0.720 |
Why?
| | Safety-net Providers | 1 | 2021 | 96 | 0.710 |
Why?
| | Male | 32 | 2023 | 57801 | 0.680 |
Why?
| | Immunization Programs | 1 | 2020 | 206 | 0.670 |
Why?
| | Needle-Exchange Programs | 2 | 2015 | 6 | 0.660 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1129 | 0.650 |
Why?
| | Research Design | 2 | 2023 | 969 | 0.640 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 88 | 0.610 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 33 | 0.600 |
Why?
| | Decision Support Techniques | 1 | 2021 | 364 | 0.600 |
Why?
| | Social Determinants of Health | 1 | 2019 | 129 | 0.590 |
Why?
| | Female | 30 | 2023 | 61565 | 0.590 |
Why?
| | Delivery of Health Care | 2 | 2021 | 867 | 0.590 |
Why?
| | Mental Disorders | 2 | 2022 | 939 | 0.580 |
Why?
| | Zinc | 1 | 2019 | 262 | 0.570 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 233 | 0.560 |
Why?
| | Young Adult | 11 | 2022 | 10793 | 0.560 |
Why?
| | Outpatients | 2 | 2020 | 325 | 0.560 |
Why?
| | Pandemics | 8 | 2022 | 1355 | 0.550 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 664 | 0.540 |
Why?
| | Guidelines as Topic | 1 | 2017 | 262 | 0.540 |
Why?
| | Monte Carlo Method | 3 | 2021 | 146 | 0.530 |
Why?
| | Criminals | 1 | 2015 | 31 | 0.520 |
Why?
| | Education | 1 | 2015 | 105 | 0.510 |
Why?
| | Emergency Medical Services | 1 | 2022 | 589 | 0.500 |
Why?
| | Blastomyces | 1 | 2014 | 8 | 0.500 |
Why?
| | Blastomycosis | 1 | 2014 | 9 | 0.500 |
Why?
| | Boston | 4 | 2021 | 76 | 0.480 |
Why?
| | Advance Directives | 1 | 2014 | 62 | 0.480 |
Why?
| | HIV Seropositivity | 1 | 2014 | 111 | 0.470 |
Why?
| | Peritonitis | 1 | 2014 | 79 | 0.470 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2022 | 765 | 0.470 |
Why?
| | Alcohol Drinking | 1 | 2019 | 652 | 0.460 |
Why?
| | Middle Aged | 15 | 2023 | 27617 | 0.440 |
Why?
| | Adolescent | 11 | 2022 | 18480 | 0.410 |
Why?
| | Retrospective Studies | 8 | 2022 | 12978 | 0.400 |
Why?
| | Quarantine | 2 | 2021 | 25 | 0.390 |
Why?
| | Injections | 2 | 2021 | 167 | 0.380 |
Why?
| | Vulnerable Populations | 2 | 2021 | 147 | 0.350 |
Why?
| | Health Services Accessibility | 3 | 2022 | 781 | 0.330 |
Why?
| | Risk-Taking | 2 | 2021 | 319 | 0.330 |
Why?
| | Coinfection | 2 | 2019 | 119 | 0.320 |
Why?
| | Harm Reduction | 2 | 2020 | 25 | 0.320 |
Why?
| | Kidney Transplantation | 1 | 2014 | 585 | 0.310 |
Why?
| | Cohort Studies | 4 | 2021 | 5116 | 0.280 |
Why?
| | Wisconsin | 3 | 2014 | 91 | 0.270 |
Why?
| | Ohio | 2 | 2022 | 141 | 0.260 |
Why?
| | Risk Factors | 4 | 2021 | 9000 | 0.260 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 687 | 0.250 |
Why?
| | Health Policy | 3 | 2022 | 333 | 0.240 |
Why?
| | Primary Health Care | 3 | 2023 | 1560 | 0.230 |
Why?
| | Cities | 1 | 2023 | 96 | 0.220 |
Why?
| | Inpatients | 3 | 2022 | 388 | 0.220 |
Why?
| | Life Expectancy | 1 | 2023 | 52 | 0.220 |
Why?
| | Quality-Adjusted Life Years | 2 | 2020 | 103 | 0.220 |
Why?
| | Colorectal Neoplasms | 1 | 2009 | 628 | 0.210 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 4552 | 0.210 |
Why?
| | Age Factors | 2 | 2020 | 2995 | 0.210 |
Why?
| | Immunogenicity, Vaccine | 1 | 2022 | 26 | 0.210 |
Why?
| | Delphi Technique | 1 | 2022 | 164 | 0.210 |
Why?
| | Arkansas | 1 | 2021 | 15 | 0.210 |
Why?
| | Ambulances | 1 | 2022 | 49 | 0.210 |
Why?
| | Quality of Life | 3 | 2022 | 2366 | 0.210 |
Why?
| | International Cooperation | 1 | 2022 | 177 | 0.210 |
Why?
| | Bayes Theorem | 1 | 2023 | 344 | 0.210 |
Why?
| | Naltrexone | 2 | 2021 | 80 | 0.200 |
Why?
| | Models, Economic | 1 | 2021 | 48 | 0.200 |
Why?
| | Needle Sharing | 1 | 2021 | 4 | 0.200 |
Why?
| | Markov Chains | 1 | 2021 | 118 | 0.200 |
Why?
| | Interrupted Time Series Analysis | 1 | 2021 | 45 | 0.200 |
Why?
| | Drug Resistance, Viral | 2 | 2022 | 98 | 0.190 |
Why?
| | Prescriptions | 1 | 2021 | 63 | 0.190 |
Why?
| | Costs and Cost Analysis | 1 | 2021 | 202 | 0.190 |
Why?
| | Homosexuality, Male | 1 | 2022 | 166 | 0.190 |
Why?
| | Health Services | 1 | 2021 | 110 | 0.190 |
Why?
| | Drug Compounding | 1 | 2021 | 90 | 0.190 |
Why?
| | Aged | 6 | 2021 | 19657 | 0.190 |
Why?
| | Sex Factors | 2 | 2020 | 1781 | 0.190 |
Why?
| | Betacoronavirus | 2 | 2020 | 254 | 0.190 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 60 | 0.180 |
Why?
| | Social Isolation | 1 | 2020 | 61 | 0.180 |
Why?
| | Patient Advocacy | 1 | 2020 | 66 | 0.180 |
Why?
| | Prescription Drugs | 1 | 2021 | 113 | 0.180 |
Why?
| | Communicable Disease Control | 1 | 2020 | 72 | 0.180 |
Why?
| | Demography | 1 | 2020 | 274 | 0.180 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 89 | 0.180 |
Why?
| | Russia | 1 | 2019 | 9 | 0.180 |
Why?
| | Public Health Administration | 1 | 2020 | 78 | 0.180 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2019 | 19 | 0.180 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2022 | 189 | 0.170 |
Why?
| | Age Distribution | 2 | 2018 | 362 | 0.170 |
Why?
| | Sex Distribution | 2 | 2018 | 351 | 0.170 |
Why?
| | Needs Assessment | 1 | 2020 | 327 | 0.170 |
Why?
| | Medicaid | 1 | 2022 | 411 | 0.170 |
Why?
| | Narcotics | 1 | 2018 | 50 | 0.160 |
Why?
| | Urban Population | 1 | 2021 | 409 | 0.160 |
Why?
| | Surgeons | 1 | 2022 | 243 | 0.160 |
Why?
| | Child | 5 | 2021 | 19129 | 0.160 |
Why?
| | Mental Health Services | 1 | 2021 | 331 | 0.150 |
Why?
| | Uridine Monophosphate | 1 | 2017 | 15 | 0.150 |
Why?
| | Rural Population | 1 | 2021 | 452 | 0.150 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1125 | 0.150 |
Why?
| | Fluorenes | 1 | 2017 | 37 | 0.150 |
Why?
| | Sofosbuvir | 1 | 2017 | 52 | 0.150 |
Why?
| | Disease Management | 1 | 2021 | 571 | 0.150 |
Why?
| | Ribavirin | 1 | 2017 | 88 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 922 | 0.140 |
Why?
| | Benzimidazoles | 1 | 2017 | 140 | 0.140 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 490 | 0.140 |
Why?
| | Obesity | 1 | 2009 | 2746 | 0.140 |
Why?
| | Recurrence | 1 | 2018 | 975 | 0.140 |
Why?
| | Skin | 1 | 2020 | 657 | 0.140 |
Why?
| | Vaccination | 2 | 2020 | 1222 | 0.130 |
Why?
| | Midwestern United States | 1 | 2015 | 38 | 0.130 |
Why?
| | Viral Load | 1 | 2017 | 419 | 0.130 |
Why?
| | Incidence | 2 | 2020 | 2424 | 0.130 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1474 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1244 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2015 | 4708 | 0.130 |
Why?
| | Health Promotion | 1 | 2021 | 691 | 0.130 |
Why?
| | Amphotericin B | 1 | 2014 | 31 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 965 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2674 | 0.120 |
Why?
| | Epidemiologic Methods | 1 | 2014 | 72 | 0.120 |
Why?
| | RNA, Viral | 1 | 2017 | 572 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2014 | 134 | 0.120 |
Why?
| | Social Stigma | 1 | 2014 | 87 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2014 | 230 | 0.110 |
Why?
| | Professional-Patient Relations | 1 | 2014 | 147 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1510 | 0.110 |
Why?
| | Genotype | 1 | 2017 | 1882 | 0.100 |
Why?
| | Physicians, Primary Care | 1 | 2014 | 222 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 794 | 0.100 |
Why?
| | Advance Care Planning | 1 | 2014 | 191 | 0.100 |
Why?
| | Internal Medicine | 1 | 2013 | 215 | 0.100 |
Why?
| | North America | 2 | 2023 | 266 | 0.100 |
Why?
| | Fear | 1 | 2014 | 307 | 0.100 |
Why?
| | Recreation Therapy | 1 | 2010 | 2 | 0.090 |
Why?
| | Pregnancy, High-Risk | 1 | 2010 | 12 | 0.090 |
Why?
| | Bed Rest | 1 | 2010 | 16 | 0.090 |
Why?
| | Evidence-Based Practice | 2 | 2023 | 193 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2021 | 5255 | 0.090 |
Why?
| | Music Therapy | 1 | 2010 | 21 | 0.090 |
Why?
| | Decision Making | 1 | 2016 | 809 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 399 | 0.090 |
Why?
| | Chronic Disease | 1 | 2014 | 1636 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 992 | 0.070 |
Why?
| | Internship and Residency | 2 | 2014 | 1001 | 0.070 |
Why?
| | Counseling | 1 | 2009 | 353 | 0.070 |
Why?
| | Anorexia | 1 | 2005 | 18 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2010 | 448 | 0.070 |
Why?
| | Cachexia | 1 | 2005 | 53 | 0.060 |
Why?
| | Recovery of Function | 1 | 2008 | 604 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2009 | 699 | 0.060 |
Why?
| | Healthcare Disparities | 1 | 2009 | 496 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2017 | 9342 | 0.060 |
Why?
| | Neoplasms | 2 | 2008 | 2179 | 0.060 |
Why?
| | Government | 1 | 2022 | 10 | 0.060 |
Why?
| | Kentucky | 1 | 2022 | 36 | 0.060 |
Why?
| | Organizations | 1 | 2022 | 19 | 0.060 |
Why?
| | Public Opinion | 1 | 2022 | 59 | 0.050 |
Why?
| | Syringes | 1 | 2022 | 37 | 0.050 |
Why?
| | Stress, Psychological | 1 | 2010 | 972 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2022 | 85 | 0.050 |
Why?
| | Oregon | 1 | 2021 | 69 | 0.050 |
Why?
| | Public Health Practice | 1 | 2022 | 62 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 128 | 0.050 |
Why?
| | British Columbia | 1 | 2020 | 17 | 0.050 |
Why?
| | Infectious Disease Medicine | 1 | 2020 | 10 | 0.050 |
Why?
| | Health Care Rationing | 1 | 2020 | 48 | 0.050 |
Why?
| | Human Rights | 1 | 2020 | 14 | 0.050 |
Why?
| | Invasive Fungal Infections | 1 | 2020 | 10 | 0.050 |
Why?
| | Federal Government | 1 | 2020 | 26 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2009 | 1185 | 0.050 |
Why?
| | Methadone | 1 | 2021 | 69 | 0.050 |
Why?
| | Delayed-Action Preparations | 1 | 2021 | 161 | 0.050 |
Why?
| | State Government | 1 | 2020 | 41 | 0.050 |
Why?
| | New York | 1 | 2020 | 118 | 0.050 |
Why?
| | Canada | 1 | 2021 | 340 | 0.050 |
Why?
| | Hepatitis B | 1 | 2020 | 52 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2020 | 132 | 0.050 |
Why?
| | Health Education | 1 | 2022 | 318 | 0.040 |
Why?
| | Specialization | 1 | 2020 | 120 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.040 |
Why?
| | Bacteremia | 1 | 2020 | 161 | 0.040 |
Why?
| | Regression Analysis | 1 | 2020 | 983 | 0.040 |
Why?
| | Patient Compliance | 1 | 2022 | 537 | 0.040 |
Why?
| | Leadership | 1 | 2020 | 311 | 0.040 |
Why?
| | Communication | 1 | 2022 | 761 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 6471 | 0.040 |
Why?
| | Societies, Medical | 1 | 2020 | 703 | 0.040 |
Why?
| | Databases, Factual | 1 | 2020 | 1231 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1284 | 0.030 |
Why?
| | Patient Readmission | 1 | 2020 | 634 | 0.030 |
Why?
| | Patient Discharge | 1 | 2020 | 796 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2014 | 237 | 0.030 |
Why?
| | Focus Groups | 1 | 2013 | 387 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2010 | 55 | 0.020 |
Why?
| | Qualitative Research | 1 | 2013 | 953 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2005 | 51 | 0.020 |
Why?
| | Psychometrics | 1 | 2005 | 631 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 2874 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 5691 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 3443 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 3057 | 0.010 |
Why?
|
|
Barocas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|